MONITORING OF PLASMA METHADONE - INTERCORRELATION BETWEEN IMMUNOASSAY AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY

被引:14
作者
BECK, O [1 ]
BOREUS, LO [1 ]
BORG, S [1 ]
JACOBSSON, G [1 ]
LAFOLIE, P [1 ]
STENSIO, M [1 ]
机构
[1] ST GORANS UNIV HOSP,DEPT PSYCHIAT,S-11281 STOCKHOLM,SWEDEN
关键词
Blood plasma; Gas chromatography; Immunoassay; Mass spectrometry; Methadone;
D O I
10.1097/00007691-199009000-00011
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Determination of plasma methadone is essential in connection with dose adjustments for patients participating in methadone maintenance programs. We successfully adapted the existing fluorescence polarization immunoassay (FPIA) kit intended for urinarymethadone to plasma assays. A concentration interval of 50–900 ng/ml could be covered. The coefficient of variation was less than 7%, and the limit of detection below 50 ng/ml. The intercorrelation between the immunoassay and a specific gas chromato-graphic-mass spectrometric (GC-MS) method was studied in samples from 19 heroin addicts in methadone maintenance treatment. A total number of 97 plasma samples with a concentration range of 31–842 ng/ml were used. The slope and intercept of the regression line (CFPIA = 0.93 x CGC-MS + 15) was in good agreement with the theoretical relation (CFPIA = CGC-MS), with a coefficient of correlation of 0.978. The mean ratio, in quantitative result, between the techniques (CFPIA CGC-MS) was 1.03 ± 0.01 (SEM). We conclude that the immunoassay proposed in this study can be safely used in patients participating in methadone maintenance programs. © 1990 Raven Press, Ltd., New York.
引用
收藏
页码:473 / 477
页数:5
相关论文
共 17 条
[1]   THE USE OF SERUM METHADONE LEVELS IN PATIENTS RECEIVING METHADONE-MAINTENANCE [J].
BELL, J ;
SERES, V ;
BOWRON, P ;
LEWIS, J ;
BATEY, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) :623-629
[2]  
CAZZOLA M, 1989, INT J CLIN PHARM RES, V9, P169
[3]   IMPLICATIONS OF METHADONE-MAINTENANCE FOR THEORIES OF NARCOTIC ADDICTION [J].
DOLE, VP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (20) :3025-3029
[4]  
FINELLI PF, 1976, NEW ENGL J MED, V294, P227
[5]  
INTURRISI CE, 1972, CLIN PHARMACOL THER, V13, P633
[6]   DRUG INTERACTIONS WITH METHADONE [J].
KREEK, MJ ;
GUTJAHR, CL ;
GARFIELD, JW ;
BOWEN, DV ;
FIELD, FH .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1976, 281 (DEC10) :350-371
[7]  
KREEK MJ, 1983, RES TREATMENT NARCOT, P95
[8]   PRELIMINARY EVALUATION OF THE ABBOTT TDX FOR BENZOYLECGONINE AND OPIATE SCREENING IN WHOLE-BLOOD [J].
MCCORD, CE ;
MCCUTCHEON, JR .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1988, 12 (05) :295-297
[9]   PHARMACOKINETICS OF METHADONE DURING MAINTENANCE TREATMENT - ADAPTIVE-CHANGES DURING THE INDUCTION-PHASE [J].
NILSSON, MI ;
ANGGARD, E ;
HOLMSTRAND, J ;
GUNNE, LM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (04) :343-349
[10]  
OLES KS, 1989, THER DRUG MONIT, V11, P471